(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Bilibili, Geo Group, and TherapeuticsMD.

Rank Financial Asset Price Change Updated (EST)
1 Bilibili (BILI) 15.43 22.56% 2022-11-29 15:52:40
2 Geo Group (GEO) 11.90 16.37% 2022-11-29 15:58:01
3 TherapeuticsMD (TXMD) 4.85 14.66% 2022-11-29 15:48:41
4 Weibo (WB) 14.75 10.16% 2022-11-29 15:45:33
5 Futu Holdings (FUTU) 58.91 10.13% 2022-11-29 15:46:58
6 Zai Lab (ZLAB) 33.92 9.24% 2022-11-29 15:53:34
7 Li Auto (LI) 18.59 9.13% 2022-11-29 15:47:14
8 RadNet (RDNT) 18.99 7.53% 2022-11-29 15:47:14
9 Niu Technologies (NIU) 3.49 6.9% 2022-11-29 15:47:32
10 JD.com (JD) 53.28 6.75% 2022-11-29 15:57:40

The three biggest losers today are Redhill Biopharma Ltd., Ohio Valley Banc Corp., and Prothena Corporation plc.

Rank Financial Asset Price Change Updated (EST)
1 Redhill Biopharma Ltd. (RDHL) 0.34 -9.23% 2022-11-29 15:15:07
2 Ohio Valley Banc Corp. (OVBC) 26.66 -8.07% 2022-11-29 01:23:14
3 Prothena Corporation plc (PRTA) 56.71 -7.35% 2022-11-29 09:14:07
4 NanoString Technologies (NSTG) 5.87 -6.97% 2022-11-28 19:14:07
5 TransCanada (TRP) 45.12 -6.79% 2022-11-29 15:48:59
6 Omnicell (OMCL) 48.63 -6.57% 2022-11-28 23:12:09
7 Nova Lifestyle (NVFY) 0.50 -6.52% 2022-11-28 19:49:17
8 Bionano Genomics (BNGO) 1.92 -6.13% 2022-11-29 15:30:52
9 ProQR Therapeutics N.V. (PRQR) 1.26 -5.97% 2022-11-29 09:13:07
10 Northwest Biotherapeutics (NWBO) 0.84 -5.59% 2022-11-28 21:06:11

Winners today

1. Bilibili (BILI) – 22.56%

Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, and live broadcasting. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Bilibili jumping 22.56% to $15.43 on Tuesday, following the last session’s upward trend. NASDAQ slid 0.59% to $10,983.78, after two sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Midday stock moves: Apple, Chevron and bilibili. Hibbett & More
Bilibili – Shares surged more than 21% after Bilibili posted better-than-expected earnings and revenue.

Earnings per Share

Bilibili’s trailing twelve-month EPS is $-1.35.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at 41.85%.

Sales Growth

Bilibili saw a 10.7% increase in sales for the current quarter, and a 10% rise for the next.

More news about Bilibili.

2. Geo Group (GEO) – 16.37%

GEO Group, Inc. (NYSE : GEO), is a major diversified provider of government services. It specializes in designing, financing, developing, and supporting secure facilities, community reentry centres, processing centers, as well as community reentry center design and development in the United States, Australia, South Africa, South Africa, and South Africa. GEO offers a variety of services, including enhanced in-custody rehabilitation, post-release support, the GEO Continuum of Care award winning program, secure transport, electronic monitoring and community-based programs. GEO also provides correctional and mental healthcare care, as well as security transportation and electronic monitoring. GEO operates worldwide and owns or delivers support services to 102 facilities, which include idle facilities, projects in development and facilities that are not yet operational. It employs approximately 18,000 people.

NYSE ended the session with Geo Group rising 16.37% to $11.90 on Tuesday, following the last session’s downward trend. NYSE jumped 0.36% to $15,425.02, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Geo Group has a trailing twelve months EPS of $0.94.

PE Ratio

Geo Group has a trailing twelve months price to earnings ratio of 12.66. Meaning,
the purchaser of the share is investing $12.66 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.46%.

Moving Average

Geo Group’s value is way higher than its 50-day moving average of $8.43 and way higher than its 200-day moving average of $7.11.

Volatility

Geo Group’s intraday variation average for the week and quarter ended last week at 0.27%. 0.95% and 2.58% respectively.

Geo Group had the highest average volatility amplitudes of 2.15%, 2.93% and 2.58% in last week.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 31.6% and positive 19.2% for the next.

Volume

Today’s last reported volume for Geo Group is 8434840 which is 308.96% above its average volume of 2062460.

More news about Geo Group.

3. TherapeuticsMD (TXMD) – 14.66%

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD rising 14.66% to $4.85 on Tuesday, after two successive sessions in a row of losses. NASDAQ slid 0.59% to $10,983.78, after two sequential sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $-0.666.

Moving Average

TherapeuticsMD’s worth is way below its 50-day moving average of $7.15 and way below its 200-day moving average of $10.00.

Revenue growth

The year-on-year revenue growth for quarterly declined 2.7%. We now have 86.42M in the 12 trailing months.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 44.7% and 89.6%, respectively.

Classification of Stock Prices

The stochastic oscillator is a helpful indicator for overbought or oversold situations.

TherapeuticsMD stock considered oversold (=20).

More news about TherapeuticsMD.

4. Weibo (WB) – 10.16%

Through its subsidiaries, Weibo Corporation operates as a social platform that allows people to share, discover, and create content in China’s People’s Republic of China. The company operates in two main segments: Advertising and Marketing Services and Value-Added Services. It offers discovery products, self-expression products and social products for users who want to share their content. The company also offers advertising and marketing services, including social display ads; promoted marketing offerings such as Fans Headline, Weibo Express and Fans Headline. It also promotes search products and trends that are displayed alongside users’ search behavior and trends discovery. The company also offers products such as trend, search, live streaming and editing tools, content customization and copyright contents pooling and user interaction development. It also provides search list recommendation and trends list recommendation. Weibo opens advertisements. It also provides traffic support and back-end management. T.CN Corporation was the company’s previous name. It changed its name in 2012 to Weibo Corporation. It was established in Beijing, China in 2009. Sina Corporation has a subsidiary called Weibo Corporation.

NASDAQ ended the session with Weibo rising 10.16% to $14.75 on Tuesday while NASDAQ dropped 0.59% to $10,983.78.

Earnings Per Share

As for profitability, Weibo has a trailing twelve months EPS of $1.38.

PE Ratio

Weibo has a trailing twelve months price to earnings ratio of 10.69. Meaning,
the purchaser of the share is investing $10.69 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.19%.

More news about Weibo.

5. Futu Holdings (FUTU) – 10.13%

Futu Holdings Limited is an online broker and wealth management company in Hong Kong. It offers trading, clearing and settlement services, margin financing, securities lending and services for stock yield enhancement. The company also provides online wealth management services through Futumoney Plus’ Futubull platform and its moomoo platform. These platforms provide access to mutual funds and private bonds, market data, information services, and NiuNiu community, where clients and users can share their insights and ask questions. The company also offers initial public offering subscriptions and employee share options plan solutions to corporate clients. Futu Holdings Limited, which was established in 2007, is located in Hong Kong.

NASDAQ ended the session with Futu Holdings jumping 10.13% to $58.91 on Tuesday, following the last session’s upward trend. NASDAQ slid 0.59% to $10,983.78, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Futu Holdings has a trailing twelve months EPS of $1.3.

PE Ratio

Futu Holdings has a trailing twelve months price to earnings ratio of 45.39. Meaning,
the purchaser of the share is investing $45.39 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.51%.

Revenue growth

The year-on-year revenue growth was 14.9%. It now stands at 6.53B in the 12 trailing months.

Growth Estimates Quarters

For the current quarter, the company expects to grow by 556.2% and 325% respectively.

Annual Top and Bottom Value

Futu Holdings’ stock was valued at $58.91 as of 16:33 EST. This is higher than the 52-week peak at $57.76.

More news about Futu Holdings.

6. Zai Lab (ZLAB) – 9.24%

Zai Lab Limited is a company that develops and markets therapies for oncology and autoimmune disorders. It also has a focus in neuroscience. Zejula is a once daily small-molecule, poly polymerase 1/2 inhibitor. Optune delivers treatment fields to tumors. NUZYRA treats skin structures and acute bacterial infections. Qinlock can treat gastrointestinal tumors. Odronextamab is also developed to treat diffuse large B cell lymphoma and other types of B-celllymphomas. Repotrectinib (a tyrosinekinase inhibitor) targets ROS1 or TRK A/B/C for patients who have been treated with TKI. Margetuximab can be used to treat breast cancer and stomach cancer. Adagrasib treats KRAS G12C-mutated NSCLC. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited, a Shanghai-based company was established in 2013.

NASDAQ ended the session with Zai Lab jumping 9.24% to $33.92 on Tuesday while NASDAQ fell 0.59% to $10,983.78.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-3.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.66%.

Annual Top and Bottom Value

At 16:33 EST Zai Lab stock was valued at $33.92, which is way lower than its 52 week high of $84.39, and much higher than its 52 week low of $20.98.

More news about Zai Lab.

7. Li Auto (LI) – 9.13%

Through its subsidiaries, Li Auto Inc. designs, develops and manufactures new energy vehicles for the People’s Republic of China. Li ONE is a smart, six-seat electric utility vehicle with ADAS navigation and emergency break functionality. The company also provides after-sales management and technology development services. It can also purchase manufacturing equipment. Li Auto Inc. was previously known as Leading Ideal Inc. Li Auto Inc. was established in 2015. It is located in Beijing, China.

NASDAQ ended the session with Li Auto rising 9.13% to $18.59 on Tuesday while NASDAQ slid 0.59% to $10,983.78.

Earnings per Share

Li Auto’s trailing 12 months earnings per share (EPS) is $-0.09.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -1.05%.

Volume

The current reported Li Auto volume is 10008400, which is 16.15% lower than its average volume (11937400).

Revenue Growth

Year-on-year quarterly revenue growth grew by 73.3%, now sitting on 36.69B for the twelve trailing months.

More news about Li Auto.

8. RadNet (RDNT) – 7.53%

RadNet, Inc. and its affiliates provide outpatient diagnostic imaging services throughout the United States. The company’s offerings include diagnostic radiology and fluoroscopy services, magnetic resonance imaging, digital tomography, positron emissions tomography (CT), nuclear medicine, mammography as well as multimodality imaging. It also designs and sells computerized systems to aid in diagnostic imaging, such as picture archiving communication systems and other related services. The company develops, deploys, and maintains AI suites that enhance radiologists’ interpretations of images within the mammography field, and AI solutions for prostate and lung cancer. It owned or managed 347 centers as of December 31, 2021 in Arizona, California and Delaware. It was established in 1981 in Los Angeles.

NASDAQ ended the session with RadNet jumping 7.53% to $18.99 on Tuesday, after five consecutive sessions in a row of gains. NASDAQ fell 0.59% to $10,983.78, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, RadNet has a trailing twelve months EPS of $-0.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.9%.

Sales Growth

RadNet’s sales growth for the next quarter is 5.3%.

Volume

RadNet’s current reported volume is 148057, which is 44% lower than its average of 264423.

Yearly Top and Bottom Value

RadNet’s stock is valued at $18.99 at 16:34 EST, way below its 52-week high of $31.20 and way above its 52-week low of $12.03.

More news about RadNet.

9. Niu Technologies (NIU) – 6.9%

Niu Technologies manufactures and sells electric scooters. NQi (MQi), UQi, Gova and Gova electric scooters/motorcycles, NIU Aero and NQi (e-bikes), RQi and Qi high-performance motorcycles, and YQi hybrid motorcycles are all available from Niu Technologies. The company also offers accessories and spare parts, including raincoats. The company also offers NIU Care, which offers maintenance and reserve service in offline service stations, NIU Repair, and DIY repair. Niu Technologies distributes its products and sells them through franchised shops, retailers, distributors, third-party online platforms, and city partners. It had 338 partners in cities and 3,108 franchised shops in around 239 Chinese cities. There were also 42 international distributors. Niu Technologies was founded in 2014. It is located in Beijing in the People’s Republic of China.

NASDAQ ended the session with Niu Technologies rising 6.9% to $3.49 on Tuesday, following the last session’s downward trend. NASDAQ dropped 0.59% to $10,983.78, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings per Share

Niu Technologies’ trailing twelve-month EPS is $0.333.

PE Ratio

Niu Technologies’ trailing 12-month price-earnings ratio is 10.53. The purchaser of the shares is investing $10.53 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the business’ profitability relative to shareholders’ equity, was 10.34%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.4%, now sitting on 3.62B for the twelve trailing months.

Volatility

Niu Technologies’s last week, last month’s, and last quarter’s current intraday variation average was 2.57%, 1.18%, and 3.77%.

Niu Technologies’s highest amplitude of average volatility was 2.72% (last week), 4.92% (last month), and 3.77% (last quarter).

More news about Niu Technologies.

10. JD.com (JD) – 6.75%

JD.com, Inc. provides supply chain-based technologies and services in the People's Republic of China. The company offers computers, communication, and consumer electronics products, as well as home appliances; and general merchandise products comprising food, beverage and fresh produce, baby and maternity products, furniture and household goods, cosmetics and other personal care items, pharmaceutical and healthcare products, books, automobile accessories, apparel and footwear, bags, and jewelry. It also provides online marketplace services for third-party merchants; marketing services; and omni-channel solutions to customers and offline retailers, as well as online healthcare services. In addition, the company develops, owns, and manages its logistics facilities and other real estate properties to support third parties; and provides asset management services for logistics property investors. Further, it provides integrated data, technology, business, and user management industry solutions to support the digitization of enterprises and institutions. The company was formerly known as 360buy Jingdong Inc. and changed its name to JD.com, Inc. in January 2014. JD.com, Inc. was incorporated in 2006 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with JD.com jumping 6.75% to $53.28 on Tuesday while NASDAQ dropped 0.59% to $10,983.78.

Earnings per Share

JD.com’s trailing 12 months profit per share is $4.89.

PE Ratio

JD.com’s trailing 12-month price-earnings ratio is 10.89. The purchaser of the shares is therefore investing $10.89 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -3.22%.

Annual Top and Bottom Value

JD.com stock was valued at $53.28 as of 16:34 EST. This is way lower than the 52-week high at $92.69, and much higher than its 52 week low at $33.17.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

JD.com’s stock is considered to be overbought (>=80).

Sales Growth

JD.com sales growth was negative 0.3% in the most recent quarter, and 4.1% the following.

Volatility

JD.com’s intraday variation average for the week and quarter ended last week was negative at 1.13% and positive at 1.43% respectively. It also stood positive at 3.43%.

JD.com had the highest average volatility amplitude at 2.62% last week, 4.17% last month and 3.43% in the quarter.

More news about JD.com.

Losers Today

1. Redhill Biopharma Ltd. (RDHL) – -9.23%

RedHill Biopharma Ltd. is a biopharmaceutical specialty company that focuses primarily on infectious and gastrointestinal diseases. Movantik, which is used to treat chronic pain in adults suffering from opioid addiction; Talicia to treat Helicobacter Pylori infections in adults; Aemcolo to treat travelers’ diarrhea in adult patients; and Movantik. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn’s disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. is an Israeli company that was established in 2009. Its headquarters are in Tel Aviv.

NASDAQ ended the session with Redhill Biopharma Ltd. falling 9.23% to $0.34 on Tuesday, after five sequential sessions in a row of losses. NASDAQ slid 0.59% to $10,983.78, after two consecutive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Redhill Biopharma Ltd. has a trailing twelve months EPS of $-2.101.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -884.29%.

More news about Redhill Biopharma Ltd..

2. Ohio Valley Banc Corp. (OVBC) – -8.07%

Ohio Valley Banc Corp. operates as the bank holding company for The Ohio Valley Bank Company that provides commercial and consumer banking products and services. The company operates in two segments, Banking and Consumer Finance. It accepts various deposit products, including checking, savings, time, and money market accounts, as well as individual retirement accounts, demand deposits, NOW accounts, and certificates of deposit. The company also provides various residential real estate loans, including one-to four-family residential mortgages; commercial loans for securing equipment, inventory, stock, commercial real estate, and rental property; and consumer loans secured by automobiles, mobile homes, recreational vehicles, and other personal property, as well as personal loans, unsecured credit card receivables, floor plan and student loans, and construction loans. In addition, it offers safe deposit boxes, wire transfers, credit card services, and Internet banking services; and financial management online services, such as cash management and news updates related to repossession auctions, current rates, and general bank news. Further, the company provides automatic teller machine (ATM) services, consumer finance, seasonal tax preparation services, and commercial property and various liability insurance services, as well as trust and online-only consumer direct mortgage services. It operates sixteen offices in Ohio and West Virginia; and six consumer finance offices in Ohio. The company owns and operates thirty- six ATMs, including twenty off-site ATMs. Ohio Valley Banc Corp. was founded in 1872 and is headquartered in Gallipolis, Ohio.

NASDAQ ended the session with Ohio Valley Banc Corp. sliding 8.07% to $26.66 on Tuesday, after two sequential sessions in a row of losses. NASDAQ slid 0.59% to $10,983.78, after two consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings per Share

Ohio Valley Banc Corp.’s trailing twelve-month EPS is $2.67.

PE Ratio

Ohio Valley Banc Corp.’s trailing 12-month price-to-earnings ratio is 9.98. The purchaser of the shares is therefore investing $9.98 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the business’ profitability relative to shareholders’ equity, was 8.43%.

Moving Average

Ohio Valley Banc Corp. is worth less than its moving average over 50 days of $27.42, and its moving average over 200 days of $29.49.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Oct 26, 2022, the estimated forward annual dividend rate is 0.84 and the estimated forward annual dividend yield is 3.21%.

Volume

Today’s last reported volume for Ohio Valley Banc Corp. is 8115 which is 18.69% above its average volume of 6837.

Annual Top and Bottom Value

At 16:35 EST Ohio Valley Banc Corp. stock was valued at $26.66. This is way lower than its 52-week peak of $32.49, and far higher than its 52 week low of $22.68.

More news about Ohio Valley Banc Corp..

3. Prothena Corporation plc (PRTA) – -7.35%

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

NASDAQ ended the session with Prothena Corporation plc falling 7.35% to $56.71 on Tuesday while NASDAQ fell 0.59% to $10,983.78.

Earnings Per Share

As for profitability, Prothena Corporation plc has a trailing twelve months EPS of $1.47.

PE Ratio

Prothena Corporation plc has a trailing twelve months price to earnings ratio of 38.58. Meaning,
the purchaser of the share is investing $38.58 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.96%.

More news about Prothena Corporation plc.

4. NanoString Technologies (NSTG) – -6.97%

NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq technologies. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

NASDAQ ended the session with NanoString Technologies falling 6.97% to $5.87 on Tuesday, after five successive sessions in a row of losses. NASDAQ dropped 0.59% to $10,983.78, after two sequential sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Earnings per Share

NanoString Technologies’ trailing 12 month EPS is $-2.78.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a business relative shareholder equity, was negative at -102.6%.

Sales Growth

NanoString Technologies’s sales growth is negative 21.1% for the current quarter and 22.6% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 20.5%, now sitting on 135.3M for the twelve trailing months.

More news about NanoString Technologies.

5. TransCanada (TRP) – -6.79%

TC Energy Corporation is an American energy infrastructure company. The company operates in five segments: Canadian Natural Gas Pipelines, U.S. Natural Gas Pipelines, Mexico Natural Gas Pipelines and Liquids Pipelines. It also provides power and storage. It operates natural gas pipelines covering 93,300km. These pipelines transport natural gas from the supply basins to power plants, distribution companies and industrial facilities. The company also owns regulated natural gas storage facilities that have a combined working gas volume of 535 Billion cubic feet. It also has approximately 4900km of liquids pipeline that links Alberta’s crude oil to refineries in Texas, Oklahoma, Texas and the U.S. Gulf Coast. The company also owns or holds interests in seven power plants with an aggregate capacity of around 4,300 megawatts. These facilities are powered by natural and nuclear fuels sources and can be found in Alberta, Ontario and Quebec. It also owns approximately 118 million cubic feet of unregulated natural gas storage in Alberta. The former name of the company was TransCanada Corporation. In May 2019, TC Energy Corporation took over its operations. TC Energy Corporation was founded in 1951. It is based in Calgary, Canada.

NYSE ended the session with TransCanada falling 6.79% to $45.12 on Tuesday while NYSE rose 0.36% to $15,425.02.

Earnings per Share

TransCanada’s trailing 12 months EPS is $3.86.

PE Ratio

TransCanada’s trailing 12-month price-earnings ratio is 11.69. The purchaser of the shares is therefore investing $11.69 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is an indicator of the business’ profitability relative to shareholders’ equity, was 10.9%.

Moving Average

TransCanada’s value exceeds its 50-day average moving price of $44.23 but is still well below its 200-day average moving price of $51.48.

Yearly Top and Bottom Value

TransCanada’s stock is valued at $45.12 at 16:35 EST, way under its 52-week high of $59.38 and way above its 52-week low of $39.11.

More news about TransCanada.

6. Omnicell (OMCL) – -6.57%

Omnicell, Inc., along with its subsidiaries, offers medication management solutions for pharmacies and healthcare systems in the United States as well as adherence tools. Omnicell, Inc. offers point-of-care automation solutions that improve the workflow of healthcare professionals in the patient care areas. It also offers XT Series automated dispenser systems for medication and supplies in the nursing unit and other areas of the hospital. Omnicell Interface Software allows integration of Omnicell’s medication-use or supply products with a facility’s information management system. There are robotic dispensing devices for stocking and retrieving boxed medicines. The company also offers central pharmacy automation systems. These include automated storage and retrieval, such as XR2 Automated Central Pharmacy Systems; IV compounding robotics, workflow management systems; inventory software, and controlled substance management system. The company also offers single-dose automation that allows you to fill and label single-dose medication blisters based on your incoming prescriptions. It can provide fully-automatic and semi-automatic filling equipment to institutional pharmacies for automated packaging. EnlivenHealth patient engagement is another web-based solution. Omnicell Technologies, Inc. was the company’s previous name. In 2001, it changed its name from Omnicell Technologies, Inc. to Omnicell, Inc. Omnicell, Inc., was founded in 1992. It is located in Mountain View, California.

NASDAQ ended the session with Omnicell sliding 6.57% to $48.63 on Tuesday while NASDAQ dropped 0.59% to $10,983.78.

Earnings per Share

Omnicell’s trailing twelve-month EPS is $1.02.

PE Ratio

Omnicell’s trailing 12-month price-earnings ratio is 47.68. The purchaser of the shares is expected to invest $47.68 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is an indicator of the business’ profitability relative to shareholders’ equity, was 4.28%.

Yearly Top and Bottom Value

Omnicell’s stock is valued at $48.63 at 16:36 EST, way under its 52-week high of $185.28 and higher than its 52-week low of $46.19.

More news about Omnicell.

7. Nova Lifestyle (NVFY) – -6.52%

Nova LifeStyle, Inc., via its subsidiaries, designs, produces, markets, sells and services residential and commercial furniture worldwide for middle- and upper-income customers. It offers furniture for living, dining, bedroom, and office spaces in upholstered and wood-based materials. Products include chairs, tables, sofas and beds. It also offers physiotherapeutic jademats that can be used in hospitality and therapy clinics. The company distributes products directly under its Diamond Sofa brand, but also through online sales and marketing campaigns and participation at exhibitions and trade fairs primarily for furniture retailers and distributors. Nova LifeStyle, Inc., a former name of Stevens Resources, Inc., was established in Commerce, California in 2003.

NASDAQ ended the session with Nova Lifestyle sliding 6.52% to $0.50 on Tuesday while NASDAQ slid 0.59% to $10,983.78.

Earnings per Share

Nova Lifestyle’s trailing 12 months profit per share is $-4.543

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -77.27%.

Volume

Today’s last reported volume for Nova Lifestyle is 6243 which is 65.6% below its average volume of 18153.

Annual Top and Bottom Value

Nova Lifestyle stock was valued at $0.50 as of 16:36 EST. This is way lower than the 52-week high at $2.08, and much higher than its 52 week low at $0.47.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.4%, now sitting on 13.41M for the twelve trailing months.

Moving Average

Nova Lifestyle’s value is way below its 50-day moving average of $0.65 and way below its 200-day moving average of $0.91.

More news about Nova Lifestyle.

8. Bionano Genomics (BNGO) – -6.13%

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

NASDAQ ended the session with Bionano Genomics falling 6.13% to $1.92 on Tuesday while NASDAQ fell 0.59% to $10,983.78.

Earnings Per Share

As for profitability, Bionano Genomics has a trailing twelve months EPS of $-0.394.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.43%.

Sales Growth

Bionano Genomics has a sales growth of 62.9% in the current quarter, and 59.8% in the next.

Yearly Top and Bottom Value

Bionano Genomics’s stock is valued at $1.92 at 16:36 EST, way below its 52-week high of $5.55 and way above its 52-week low of $1.16.

Moving Average

Bionano Genomics is far below its $50-day moving mean of $2.18, and well below its $200-day moving median of $2.03.

More news about Bionano Genomics.

9. ProQR Therapeutics N.V. (PRQR) – -5.97%

ProQR Therapeutics N.V. is a biopharmaceutical firm that specializes in developing RNA-based therapies for genetic disorders. The company focuses on developing sepofarsen which is currently in the phase II/III clinical trials illuminate trial for leber congenital autism 10; and ultevursen which is currently in phase II/III to treat USH2A mediated retinitis pigmentosa. Axiomer is also involved in developing Axiomer’s RNA-base-editing platform technology. The company has an agreement for license with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. It also collaborates with Eli Lilly and Company to license and conduct research for potential medicines that could be used for treating genetic disorders of the nervous system and liver. ProQR Therapeutics N.V., which was established in 2012 is located in Leiden (the Netherlands).

NASDAQ ended the session with ProQR Therapeutics N.V. falling 5.97% to $1.26 on Tuesday, after four successive sessions in a row of losses. NASDAQ fell 0.59% to $10,983.78, after two consecutive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings per Share

ProQR Therapeutics N.V.’s trailing 12 months EPS is $-0.96.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -74.51%.

Moving Average

ProQR Therapeutics N.V. is worth a lot more than its moving average 50 days of $0.93, and its moving average 200 days of $0.86.

Volume

Today’s last reported volume for ProQR Therapeutics N.V. is 530512 which is 22.33% below its average volume of 683087.

More news about ProQR Therapeutics N.V..

10. Northwest Biotherapeutics (NWBO) – -5.59%

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

NASDAQ ended the session with Northwest Biotherapeutics falling 5.59% to $0.84 on Tuesday while NASDAQ fell 0.59% to $10,983.78.

Earnings per Share

Northwest Biotherapeutics’ trailing 12 months profit per share was $-0.063.

More news about Northwest Biotherapeutics.

Stay up to date with our winners and losers daily report